Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | FADS1 | O60427 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31424193 | 1.00 | MEN1 (0.72) | MEN1KMT2AALDH1A1FADS1L3MBTL1 | |
| SCHEMBL17744881 | 0.90 | FADS1 (0.72) | MEN1KMT2AALDH1A1FADS1PTGS1 | |
| SCHEMBL1961258 | 0.87 | FADS1 (0.69) | MEN1KMT2AALDH1A1FADS1PTGS1 | |
| SCHEMBL5668766 | 0.86 | FADS1 (0.68) | MEN1KMT2AALDH1A1FADS1PTGS1 | |
| SCHEMBL4924293 | 0.86 | MEN1 (0.75) | MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL533767 | 0.85 | KCNK3 (0.81) | MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9810110 | 0.85 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1FADS1PTGS1 | |
| SCHEMBL5668126 | 0.84 | FADS1 (0.65) | MEN1KMT2AALDH1A1FADS1PTGS1 | |
| SCHEMBL8485797 | 0.84 | FADS1 (0.65) | MEN1KMT2AALDH1A1FADS1PTGS1 | |
| SCHEMBL3356211 | 0.84 | MEN1 (1.00) | MEN1KMT2AALDH1A1L3MBTL1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661459-A | 1,2, 3-Benzotriazine-4 (3H) -one seleno compound and preparation method and application thereof | 赣南师范大学 | 2025-03-21 | — | — | CN | claimed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| CN-119661459-A | 1,2, 3-Benzotriazine-4 (3H) -one seleno compound and preparation method and application thereof | 赣南师范大学 | 2025-03-21 | — | — | CN | disclosed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-9486455-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486455-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| CN-1268949-A | Fused thiophene compounds and medical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-0817629-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0817629-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5631280-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996030014-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | MEN1 4683/4885KMT2A 4347/4885ALDH1A1 3074/4885 |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | MEN1 4683/4885KMT2A 4347/4885ALDH1A1 3074/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | MEN1 3106/4885KMT2A 2832/4885ALDH1A1 978/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | MEN1 4745/4885KMT2A 2604/4885ALDH1A1 2909/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | MEN1 4701/4885KMT2A 2692/4885ALDH1A1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.